Table of Contents
1. Executive Summary
2. Market Overview
3. Animal Health Pipeline Overview
4. Companion Animal Therapeutic Pipeline
5. Livestock Pipeline
6. Aquaculture Pipeline
7. Veterinary Diagnostic Pipeline
8. Monoclonal Antibody Pipeline
9. mRNA Veterinary Vaccines
10. Gene Therapy and Cell Therapy
11. AI-Enabled Diagnostics
12. Approval Timeline 2026-2030
13. Pipeline Risk Assessment
14. Strategic Conclusions and Recommendations
15. Appendix

List of Tables
Table 1. Animal Health Pipeline Overview by Phase 2026
Table 2. Companion Animal Therapeutic Pipeline by Indication
Table 3. Livestock Therapeutic and Vaccine Pipeline
Table 4. Aquaculture Pipeline by Species and Indication
Table 5. Veterinary Diagnostic Pipeline by Modality
Table 6. Monoclonal Antibody Pipeline by Supplier
Table 7. mRNA Veterinary Vaccine Pipeline
Table 8. Gene Therapy and Cell Therapy Pipeline
Table 9. AI Diagnostic Platforms in Development
Table 10. Approval Timeline 2026-2030 by Supplier
 

List of Figures
Figure 1. Animal Health Pipeline Overview by Phase
Figure 2. Pipeline Mix by Therapeutic Category
Figure 3. Companion vs. Livestock vs. Aquaculture Pipeline
Figure 4. Top 10 Supplier Pipeline Comparison
Figure 5. mAb Pipeline Heatmap
Figure 6. mRNA and Gene Therapy Pipeline Activity
Figure 7. Approval Timeline 2026-2030
Figure 8. Pipeline Value Estimation by Indication
 

Companies Profiled
Boehringer Ingelheim Animal Health
Ceva Santé Animale
Dechra Pharmaceuticals
Elanco Animal Health
IDEXX Laboratories
Merck Animal Health
Phibro Animal Health
Vetoquinol
Virbac
Zoetis